Dandekar Atul has filed a report detailing recent transactions involving common stock of Maze Therapeutics, Inc. This filing is significant as it highlights Atul's ongoing engagement with the company as its Chief Strategy and Business Officer. The transactions indicate a proactive approach to managing his equity stake in the firm.

Background

Dandekar Atul is an executive affiliated with Maze Therapeutics, Inc., a company focused on biological products. The recent filing, dated October 30, 2026, includes transactions reported under Form 4. Maze Therapeutics operates within the life sciences sector and is listed under the SIC classification for biological products.

What the Filing Says

In the filing, Atul reported multiple transactions dated October 29, 2026. He acquired 6,643 shares and 857 shares of Maze Therapeutics' common stock at a price of $10.42 per share. Additionally, he disposed of 7,500 shares at a weighted average price of $32.07, with the filing noting that this sale was part of a Rule 10b5-1 trading plan adopted on September 29, 2025.

Impact

This update may influence investor sentiment regarding Maze Therapeutics, as Atul's stock activities reflect his confidence in the company's future. The transactions could also impact other stakeholders, including current shareholders and potential investors, as they assess the company's leadership and strategic direction.

What's Next

The filing does not say what happens next.